CUE (Cue Biopharma) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CUE Cue Biopharma Inc CUE
45 GF Score
Price $33.18
! 5 Warning Signs
View Full Analysis

What is Cue Biopharma Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

CUE
45GF Score
Cue Biopharma Inc CUE
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cue Biopharma Business Description

Other Exchanges 1UC0:Germany
Address 40 Guest Street, Boston, MA, USA, 02135
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
45GF Score

Get the complete analysis for CUE

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$33.18
Price